Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


Paradigms for Precision Medicine in Epichaperome Cancer Therapy.

Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, Wang T, Lecomte N, Janjigian Y, Younes A, Batlevi CW, Guzman ML, Roboz GJ, Koziorowski J, Zanzonico P, Alpaugh ML, Corben A, Modi S, Norton L, Larson SM, Lewis JS, Chiosis G, Gerecitano JF, Dunphy MPS.

Cancer Cell. 2019 Nov 11;36(5):559-573.e7. doi: 10.1016/j.ccell.2019.09.007. Epub 2019 Oct 24.


Pharmacokinetic assessment of 18F-(2S,4R)-4-fluoroglutamine in patients with cancer.

Grkovski M, Goel R, Krebs S, Staton KD, Harding JJ, Mellinghoff IK, Humm JL, Dunphy MP.

J Nucl Med. 2019 Oct 10. pii: jnumed.119.229740. doi: 10.2967/jnumed.119.229740. [Epub ahead of print]


Chaperome heterogeneity and its implications for cancer study and treatment.

Wang T, Rodina A, Dunphy MP, Corben A, Modi S, Guzman ML, Gewirth DT, Chiosis G.

J Biol Chem. 2019 Feb 8;294(6):2162-2179. doi: 10.1074/jbc.REV118.002811. Epub 2018 Nov 8. Review.


In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.

Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS.

Radiology. 2018 May;287(2):667-675. doi: 10.1148/radiol.2017162610. Epub 2018 Jan 31.


Solitary Orbital Metastasis in Carcinoma Esophagus: Findings on Serial 18F-FDG PET/CT Scans.

Mahajan S, Dunphy MP, Haque S, Pandit-Taskar N.

Clin Nucl Med. 2018 Jan;43(1):19-22. doi: 10.1097/RLU.0000000000001892.


Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Kim MM, Parolia A, Dunphy MP, Venneti S.

Nat Rev Clin Oncol. 2016 Dec;13(12):725-739. doi: 10.1038/nrclinonc.2016.108. Epub 2016 Jul 19. Review.


The epichaperome is an integrated chaperome network that facilitates tumour survival.

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G.

Nature. 2016 Oct 20;538(7625):397-401. doi: 10.1038/nature19807. Epub 2016 Oct 5.


Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.

Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Koziorowski J, Dunphy MP, Zanzonico P, Bolaender A, Lewis JS, Larson SM, Chiosis G, Pillarsetty NV.

J Labelled Comp Radiopharm. 2016 Mar;59(3):129-32. doi: 10.1002/jlcr.3369. Epub 2016 Jan 25.


Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo.

Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB.

Sci Transl Med. 2015 Feb 11;7(274):274ra17. doi: 10.1126/scitranslmed.aaa1009.


Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.

Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J 3rd, Modi S, Chiosis G.

Expert Opin Investig Drugs. 2014 May;23(5):611-28. doi: 10.1517/13543784.2014.902442. Epub 2014 Mar 26. Review.


Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2 cm.

Nitadori J, Bograd AJ, Morales EA, Rizk NP, Dunphy MP, Sima CS, Rusch VW, Adusumilli PS.

Ann Surg Oncol. 2013 Dec;20(13):4282-8. doi: 10.1245/s10434-013-3212-2. Epub 2013 Aug 17.


FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

Kadota K, Colovos C, Suzuki K, Rizk NP, Dunphy MP, Zabor EC, Sima CS, Yoshizawa A, Travis WD, Rusch VW, Adusumilli PS.

Ann Surg Oncol. 2012 Oct;19(11):3598-605. doi: 10.1245/s10434-012-2414-3. Epub 2012 May 30.


High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.

Kadota K, Kachala SS, Nitadori J, Suzuki K, Dunphy MP, Sima CS, Travis WD, Rusch VW, Adusumilli PS.

J Thorac Oncol. 2012 Jul;7(7):1192-7. doi: 10.1097/JTO.0b013e3182519d96.


Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.

Dunphy MP, Zanzonico P, Veach D, Somwar R, Pillarsetty N, Lewis J, Larson S.

Mol Imaging Biol. 2012 Feb;14(1):25-31. doi: 10.1007/s11307-010-0462-2.


Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Dunphy MP, Lewis JS.

J Nucl Med. 2009 May;50 Suppl 1:106S-21S. doi: 10.2967/jnumed.108.057281. Epub 2009 Apr 20. Review.


In vivo microcartography and subcellular imaging of tumor angiogenesis: a novel platform for translational angiogenesis research.

Dunphy MP, Entenberg D, Toledo-Crow R, Larson SM.

Microvasc Res. 2009 Jun;78(1):51-6. doi: 10.1016/j.mvr.2009.03.008. Epub 2009 Apr 9.


Molecular imaging of atherosclerosis.

Dunphy MP, Strauss HW.

Curr Cardiol Rep. 2008 Mar;10(2):121-7. Review.


Radionuclide techniques for identifying vulnerable plaque.

Dunphy MP, Schoder H, Strauss HW.

J Nucl Med. 2007 Nov;48(11):1753-5. No abstract available.


Association of vascular 18F-FDG uptake with vascular calcification.

Dunphy MP, Freiman A, Larson SM, Strauss HW.

J Nucl Med. 2005 Aug;46(8):1278-84.


A postdischarge adverse drug reaction capture mechanism using medical record technicians.

Voris JC, Dunphy MP.

QRB Qual Rev Bull. 1991 Sep;17(9):293-6.


Supplemental Content

Loading ...
Support Center